ROCKVILLE, Md., Dec. 1, 2017 /PRNewswire/ -- CASI
Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company
dedicated to innovative therapeutics addressing cancer and other
unmet medical needs announces a poster presentation on ENMD-2076 at
the 2017 San Antonio Breast Cancer SymposiumTM (SABCS),
December 5-9, 2017 in San Antonio, Texas.
ENMD-2076 is currently in a Phase 2 trial for the treatment of
triple-negative breast cancer (TNBC) at two locations in the U.S.
The poster will be presented in the session listed below and will
be available on the CASI Pharmaceuticals website after the
conclusion of the presentation.
Program Number: PD3-16
Abstract Number: 272
Session Title: Novel Drugs / Predicting Response for HER2+ Breast
Cancer
Session Date: Thursday, December 7,
2017
Session Time: 7:00:00 AM –
9:00:00 AM CST
Title: "Clinical Safety and Efficacy of the Aurora and Angiogenic
Kinase Inhibitor ENMD-2076 in Previously Treated, Locally Advanced
or Metastatic Triple-Negative Breast Cancer"
About CASI Pharmaceuticals, Inc.
CASI is a U.S. based, late-stage biopharmaceutical company
focused on the acquisition, development and commercialization of
innovative therapeutics addressing cancer and other unmet medical
needs for the global market with a focus on commercialization in
China. CASI's product pipeline
features (1) EVOMELA®, MARQIBO® and
ZEVALIN®, all U.S. Food and Drug Administration (FDA)
approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for
China regional rights, and
currently in various stages in the regulatory and clinical process
for market approval in China, (2)
CASI-001 and CASI-002, proprietary preclinical candidates in
immune-oncology, and (3) our proprietary drug candidate, ENMD-2076,
ongoing in one Phase 2 clinical study. CASI is headquartered in
Rockville, Maryland and has a
wholly owned subsidiary and R&D operations in Beijing, China. More information on CASI is
available at www.casipharmaceuticals.com and in CASI's filings with
the U.S. Securities and Exchange Commission.
CASI's China rights to
EVOMELA® (melphalan) for Injection, MARQIBO®
(vinCRIStine sulfate LIPOSOME injection) and ZEVALIN®
(ibritumomab tiuxetan) were previously licensed from its partner
Spectrum Pharmaceuticals, Inc. Based on the U.S. FDA's approval of
these three licensed products, CASI is pursuing the Import Drug
registration path for approval in China.
Forward Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act with
respect to the outlook for expectations for future financial or
business performance, strategies, expectations and
goals. Forward looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time.
Forward-looking statements speak only as of the date they are made,
and no duty to update forward-looking statements is assumed. Actual
results could differ materially from those currently anticipated
due to a number of factors, including: that we may be unable to
continue as a going concern as a result of our inability to raise
sufficient capital for our operational needs; the volatility in the
market price of our common stock; risks relating to interests of
our largest stockholders that differ from our other stockholders;
the risk of substantial dilution of existing stockholders in future
stock issuances, the difficulty of executing our business strategy
in China; our inability to predict
when or if our product candidates will be approved for marketing by
the China Food and Drug Administration authorities; our inability
to enter into strategic partnerships for the development,
commercialization, manufacturing and distribution of our proposed
product candidates or future candidates; risks relating to the need
for additional capital and the uncertainty of securing additional
funding on favorable terms; risks associated with our product
candidates; risks associated with any early-stage products under
development; the risk that results in preclinical and early
clinical models are not necessarily indicative of later clinical
results; uncertainties relating to preclinical and clinical trials,
including delays to the commencement of such trials; the lack of
success in the clinical development of any of our products;
dependence on third parties; and risks relating to the
commercialization, if any, of our proposed products (such as
marketing, safety, regulatory, patent, product liability, supply,
competition and other risks). Such factors, among others, could
have a material adverse effect upon our business, results of
operations and financial condition. We caution readers not to place
undue reliance on any forward-looking statements, which only speak
as of the date made. Additional information about the factors and
risks that could affect our business, financial condition and
results of operations, are contained in our filings with the U.S.
Securities and Exchange Commission, which are available at
www.sec.gov.
EVOMELA®, MARQIBO® and
ZEVALIN® are proprietary to Spectrum
Pharmaceuticals, Inc. and its affiliates.
COMPANY
CONTACT:
CASI Pharmaceuticals,
Inc.
240.864.2643
ir@casipharmaceuticals.com
|
INVESTOR
CONTACT:
Torrey Hills
Capital
Jim
Macdonald
858.456.7300
jm@sdthc.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-poster-presentation-at-the-2017-san-antonio-breast-cancer-symposiumtm-sabcs-on-enmd-2076-in-patients-with-triple-negative-breast-cancer-tnbc-300564581.html
SOURCE CASI Pharmaceuticals, Inc.